2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology 2014, 17: 440-447. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.Peer-Reviewed Original ResearchConceptsProgression-free survivalClinical courseEpendymoma patientsMultivariate Cox proportional hazards modelMultivariate Cox proportional hazardsCox proportional hazards modelRare CNS tumorsTime of diagnosisPrognostic clinical factorsCox proportional hazardsProportional hazards modelSubtotal resectionClinical factorsMedian timeCNS tumorsCentral reviewGrade IIIMean ageTumor recurrenceEarly progressionTumor locationGrade IITumor gradeUnivariate analysisSupratentorial location
2007
Editorial: what is new in the treatment of gliomas?
Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Current Opinion In Neurology 2007, 20: 704-707. PMID: 17992093, DOI: 10.1097/wco.0b013e3282f1beef.Peer-Reviewed Original ResearchConceptsTreatment of gliomaTherapeutic decisionsEvidence-based therapeutic decisionsBevacizumab-based combinationsRecurrent malignant gliomaRole of chemotherapyPhase II trialStandard of carePhase III evidenceHigh response ratePhase II resultsSingle positive resultTemozolomide concomitantTemozolomide schedulesII trialSurvival benefitRandomized trialsGrade IIIMalignant gliomasResponse rateGliomasSuch trialsTraditional treatmentTrialsCodeletion status